Yoshiko Iwai

Tokyo, 1138602, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma.

Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma.

Journal: Scientific reports

Published: September 19, 2025

Efficacy of Adding Immune Checkpoint Inhibitors to Chemotherapy Plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

Efficacy of Adding Immune Checkpoint Inhibitors to Chemotherapy Plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

Journal: Cancers

Published: June 19, 2025

MALAT1 regulates human macrophage metabolism by interacting with HADHB.

MALAT1 regulates human macrophage metabolism by interacting with HADHB.

Journal: iScience

Published: June 06, 2025

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.

Journal: Frontiers in pharmacology

Published: February 10, 2024

Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.

Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.

Journal: Frontiers in pharmacology

Published: February 10, 2024

Interleukin 21 promotes IgG1+ plasma cell differentiation instead of class switching to IgE via Blimp1 expression.

Interleukin 21 promotes IgG1+ plasma cell differentiation instead of class switching to IgE via Blimp1 expression.

Journal: European journal of immunology

Published: January 31, 2024

THE DEVELOPMENT OF CANCER IMMUNOTHERAPY: REGULATORY MECHANISM OF T CELL RESPONSE

THE DEVELOPMENT OF CANCER IMMUNOTHERAPY: REGULATORY MECHANISM OF T CELL RESPONSE

Journal: Arerugi = [Allergy]

Published: September 11, 2022

Targeting the Chemokine System in Rheumatoid Arthritis and Vasculitis.

Targeting the Chemokine System in Rheumatoid Arthritis and Vasculitis.

Journal: JMA journal

Published: March 30, 2020

Development of Cancer Immunotherapy Targeting the PD-1 Pathway.

Development of Cancer Immunotherapy Targeting the PD-1 Pathway.

Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Published: March 29, 2019

Rap1b Promotes Notch-Signal-Mediated Hematopoietic Stem Cell Development by Enhancing Integrin-Mediated Cell Adhesion.

Rap1b Promotes Notch-Signal-Mediated Hematopoietic Stem Cell Development by Enhancing Integrin-Mediated Cell Adhesion.

Journal: Developmental cell

Published: July 15, 2018

Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.

Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.

Journal: Immunology letters

Published: November 10, 2017

Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.

Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.

Journal: Journal of surgical oncology

Published: November 08, 2017

Showing 1-12 of 20

Last Updated: 09/26/2026